New strategic role in global osteoarthritis research

Ida K. Bos-Haugen has been given a new and more influential role in Osteoarthritis Research Society International (OARSI). The news was announced at the OARSI World Congress on Osteoarthritis this year.

As the newly elected Secretary of OARSI, she is now a member of the organization's executive committee – a subgroup of the board responsible for strategic leadership, governance and daily operations. OARSI is a global organization focused on advancing osteoarthritis research.

– This provides a unique opportunity to influence the osteoarthritis field internationally, both in terms of research, collaboration and priorities, says Bos-Haugen.

Long experience in OARSI

The new role builds on several years in key positions. Bos-Haugen was a board member from 2019 to 2024 and secretary from 2021 to 2024. She has now been re-elected as secretary for the period 2024–2026.

Through these roles, she has contributed to strengthening international collaboration in osteoarthritis research.

Research on osteoarthritis

Professor Ida K. Bos-Haugen is a rheumatologist and researcher at the REMEDY Center at Diakonhjemmet Hospital. Her research focuses on hand osteoarthritis and how to better understand and treat the causes of pain. At the REMEDY Center, she is part of an environment that works to translate research-based knowledge into more accurate treatment and more efficient healthcare services.

OARSI

OARSI is an international, interdisciplinary organization that brings together osteoarthritis researchers from all over the world. The goal is to increase knowledge about osteoarthritis and improve prevention, diagnosis and treatment. The World Congress was held April 23-26, 2026

Osteoarthritis is one of the most common causes of pain and disability globally. OARSI therefore plays a central role in influencing the research agenda and contributing to the translation of new knowledge into practice.

With Bos-Haugen's new role, Norway will have a clearer voice in this work. It could provide increased visibility for Norwegian research – and in the long term, better treatment for patients.